Sage Bluff Health & Rehab Center | |
4180 Sage Bluff Crossing, Fort Wayne, Indiana 46804 | |
(260) 443-7300 | |
Name | Sage Bluff Health & Rehab Center |
---|---|
Location | 4180 Sage Bluff Crossing, Fort Wayne, Indiana |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 84 |
Occupancy Rate | 60.48% |
Medicare ID (CCN) | 155827 |
Legal Business Name | Major Hospital |
Ownership Type | For Profit - Corporation |
NPI Number | 1336557511 |
Organization Name | MAJOR HOSPITAL |
Doing Business As | SAGE BLUFF HEALTH & REHAB CENTER LLC |
Address | 4180 Sage Bluff Crossing, Fort Wayne, IN 46804 |
Phone Number | 260-443-7300 |
News Archive
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.
ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
As efforts are underway to keep the season going under existing restrictions, a preprint research paper appearing on the medRxiv server describes the estimated incidence and the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among European soccer players.
› Verified 7 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.
ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
As efforts are underway to keep the season going under existing restrictions, a preprint research paper appearing on the medRxiv server describes the estimated incidence and the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among European soccer players.
› Verified 7 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $6500 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 19.59 | 14.46 |
Percentage of long-stay residents who lose too much weight | 6.16 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 51.22 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.59 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 4.32 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 1.9 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.49 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 90.12 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 8.93 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 63.11 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.17 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 18.43 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.67 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 8.59 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 87.18 | 95.98 |
Percentage of short-stay residents who made improvements in function | 54.89 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 69.54 | 82.93 |
News Archive
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.
ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.
AdvanSource Biomaterials Corporation, a leading developer of advanced polymer materials for a broad range of medical devices, today announced it has entered into a multi-year supply agreement with an international medical diagnostics device company engaged in the business of developing medical device coatings and developing, manufacturing and selling coated medical devices.
As efforts are underway to keep the season going under existing restrictions, a preprint research paper appearing on the medRxiv server describes the estimated incidence and the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among European soccer players.
› Verified 7 days ago
Summit City Nursing And Rehabilitation Location: 2940 N Clinton St, Fort Wayne, Indiana 46805 Phone: (260) 484-0602 | |
Glenbrook Rehabilitation & Skilled Nursing Center Location: 3811 Parnell Ave, Fort Wayne, Indiana 46805 Phone: (260) 482-4651 | |
Signature Healthcare Of Fort Wayne Location: 6006 Brandy Chase Cove, Fort Wayne, Indiana 46815 Phone: (260) 486-3001 | |
Elevate Senior Living - Fort Wayne Location: 3420 East State Blvd, Fort Wayne, Indiana 46805 Phone: (260) 484-3120 | |
Life Care Center Of Fort Wayne Location: 1649 Spy Run Avenue, Fort Wayne, Indiana 46805 Phone: (260) 422-8520 |